The DUSP10 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, featuring targeted disruption of the DUSP10 gene. This loss-of-function model enables researchers to investigate the dual-specificity phosphatase DUSP10 without the confounding effects of wild-type protein expression. The polyclonal pool harbors a variety of CRISPR-induced genetic alterations at the target locus, providing a robust representation of DUSP10 deficiency across the cell population. This reagent is optimized for experiments where complete gene inactivation at the polyclonal level is sufficient to dissect pathway contributions, bypassing the need for single-cell cloning while preserving the genetic heterogeneity inherent to polyclonal populations.
The parental HeLa line is a well-established immortalized cervical adenocarcinoma cell line, positive for human papillomavirus type 18 (HPV18). As an epithelial model, HeLa cells are extensively employed in cancer research due to their robust growth, ease of manipulation, and well-characterized signaling networks. Their origin in cervical cancer makes them particularly relevant for studies of oncogenic transformation, viral oncoprotein interactions, and tumor cell signaling. The retention of key stress-responsive pathways, including the MAPK cascades, positions this knockout model to address fundamental questions in tumor cell biology.
DUSP10, also known as MKP5, encodes a dual-specificity phosphatase that negatively regulates the MAPK signaling cascades by dephosphorylating both phosphothreonine and phosphotyrosine residues on activated JNK and p38 kinases. Mechanistically, DUSP10 is activated by upstream stressors such as oxidative stress and inflammatory cytokines including TNF-alpha and IL-1, and it directly interacts with and dephosphorylates JNK1, JNK2, JNK3, and the p38 isoforms (alpha, beta, gamma, delta), thereby terminating signal propagation. This places DUSP10 downstream of MAP3Ks like ASK1 and MEKK1 and the MAP2Ks MKK4, MKK7, MKK3, and MKK6, with scaffold proteins such as JIP often coordinating complex assembly. Consequently, DUSP10 acts as a critical brake on JNK and p38 signaling, controlling the activity of downstream transcription factors like c-Jun and ATF2, which are key effectors in stress responses, apoptosis, and proliferation.
In the HeLa cellular context, loss of DUSP10 is expected to result in sustained or exaggerated activation of the JNK and p38 modules upon stimulation, altering the cellular stress response, apoptosis thresholds, and proliferation dynamics. Given the dual role of DUSP10 as either tumor suppressor or promoter depending on cancer type and microenvironment, this model offers a unique tool to parse its functions in cervical adenocarcinoma and other epithelial cancers. The HPV18-positive background further enables investigation of crosstalk between viral oncoproteins and host stress-signaling networks, with relevance to colorectal, gastric, and breast cancers where DUSP10 dysregulation has been implicated. Moreover, the hyperactivated MAPK state may illuminate mechanisms of drug resistance and sensitivity in the context of epithelial malignancies.
This knockout cell population is ideally suited for a broad array of experimental applications. Researchers can employ Western blotting to quantify phosphorylated JNK and p38 levels, RT-qPCR to assess expression changes in DUSP10 target genes, and apoptosis or proliferation assays to measure functional outcomes of heightened MAPK activity. AP-1 reporter assays enable direct readouts of JNK/p38-dependent transcriptional activity. Additionally, phospho-signaling analyses and drug sensitivity studies can reveal the impact of DUSP10 loss on therapeutic responses. These cells thus provide a powerful platform to dissect MAPK regulation, cellular stress responses, inflammatory signaling, and cancer cell survival mechanisms. For further information or technical assistance, please contact Ascent Research.
